Pessina, Patrizia https://orcid.org/0000-0002-4227-411X
Nevo, Mika https://orcid.org/0000-0002-2385-4784
Shi, Junchao https://orcid.org/0000-0002-1548-5069
Kodali, Srikanth
Casas, Eduard
Cui, Yingzhi
Richards, Alicia L.
Park, Emily J. https://orcid.org/0000-0001-8770-9239
Chen, Xi
Levin-Ferreyra, Florencia
Rivera Tostado, Alejandra
Stevenson, Erica
Krogan, Nevan J. https://orcid.org/0000-0003-4902-337X
Swaney, Danielle L. https://orcid.org/0000-0001-6119-6084
Ying, Qilong https://orcid.org/0000-0001-5822-9498
Chen, Qi https://orcid.org/0000-0001-6353-9589
Brumbaugh, Justin https://orcid.org/0000-0002-9605-2010
Di Stefano, Bruno https://orcid.org/0000-0003-2532-3087
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1R35GM147126)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM142607)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM142884)
American Society of Hematology (Scholar Award)
Worldwide Cancer Research (24-0037)
Cancer Prevention and Research Institute of Texas (RR200079)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R21AI193649)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA291649)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F32 CA288043-01)
The Andrew McDonough B+ Foundation
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (1F30HD114315)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01 HL146366)
Article History
Received: 9 January 2025
Accepted: 9 September 2025
First Online: 28 October 2025
Competing interests
: N.J.K.’s laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche and Rezo Therapeutics. N.J.K. is the president and is on the board of directors of Rezo Therapeutics, and he is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, GEn1E Lifesciences and Interline Therapeutics. N.J.K. also has financially compensated consulting agreements with the Icahn School of Medicine at Mount Sinai, New York, Interline Therapeutics, Rezo Therapeutics, GEn1E Lifesciences and Twist Bioscience (all within the last 36 months). The other authors declare no competing interests.